Quidelortho Corp (QDEL) Stock Price, Quote & News

Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, ant...

Industry: Medical Devices

Sector: Healthcare

Phone: 858 552 1100

Fax: 858 453 4338

Website: www.quidelortho.com

Address:

9975 Summers Ridge Road, San Diego, United States

VolatilityControl Feb. 18 at 4:40 PM

$QDEL QuidelOrtho operates diagnostics platforms with cyclical testing demand. Margin recovery depends on cost control. Base business remains stable.

0 · Reply

Staska Feb. 18 at 4:30 PM

$QDEL Catalysts in Upcoming Quarters Looking ahead, our analysts are monitoring (1) the pace and impact of new platform launches, including VITROS 450 and LEX Diagnostics; (2) progress on procurement and facility optimization initiatives to support margin expansion; and (3) international market growth, particularly in Latin America, Asia Pacific, and OUS immunoassay tenders. Regulatory developments in China and the sustainability of Labs segment momentum will also be closely tracked.

0 · Reply

Staska Feb. 18 at 4:28 PM

$QDEL Our Top 5 Analyst Questions From QuidelOrtho’s Q4 Earnings Call Tycho Peterson (Jefferies) asked about the sustainability of Labs growth. CFO Joseph Busky highlighted ongoing adoption in clinical chemistry and underpenetrated immunoassay markets, noting, “Our low OUS market penetration continues to be a growth opportunity.” Jack Meehan (Nephron) pressed for updates on China’s potential value-based procurement (VBP) changes. CEO Brian Blaser said there was no new information and estimated a possible 0.5% to 1% revenue impact if QuidelOrtho products were included. Andrew Brackmann (William Blair) questioned the assumptions behind the wide EPS guidance range. Busky attributed it largely to unpredictable respiratory volumes and higher depreciation due to instrument placements and ERP investments. https://finance.yahoo.com/news/top-5-analyst-questions-quidelortho-053643737.html

1 · Reply

BillionerOfKing Feb. 18 at 2:05 PM

$QDEL Current Stock Price: $23.14 Contracts to trade: $22.5 QDEL Feb 20 2026 Call Entry: $1.08 Exit: $1.39 ROI: 29% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Feb. 17 at 5:05 PM

$QDEL's strategic move: Is it a step forward for international growth? 🌍 QuidelOrtho's new agreement with Lifotronic Technology expands its immunoassay portfolio, adding over 25 new assays to strengthen its position in international lab tenders. Discover the full strategic impact here 👉 https://www.zacks.com/stock/news/2870608/qdel-expands-immunoassay-portfolio-via-lifotronic-supply-agreement?cid=sm-stocktwits-2-2870608-body-33839&ADID=SYND_STOCKTWITS_TWEET_2_2870608_BODY_33839

0 · Reply

ZacksResearch Feb. 17 at 4:05 PM

$QDEL just made a quiet but meaningful expansion move — and it’s all about scale 📈 QuidelOrtho signed a Lifotronic supply agreement, adding 70+ assays and new analyzer platforms to expand its global immunoassay reach and strengthen recurring revenue potential. Broader menu + more platforms = deeper customer stickiness. See what this means for the investment case 👉 https://www.zacks.com/stock/news/2870608/qdel-expands-immunoassay-portfolio-via-lifotronic-supply-agreement?cid=sm-stocktwits-2-2870608-teaser-33817&ADID=SYND_STOCKTWITS_TWEET_2_2870608_TEASER_33817

0 · Reply

Staska Feb. 17 at 12:23 PM

$QDEL QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of over 70 assays on these new partner platforms. These additions are planned to increase QuidelOrtho's ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger, high-throughput environments that require scalable capacity and broad test menus. https://ir.quidelortho.com/news/news-release-details/2026/QuidelOrtho-Enters-Strategic-Supply-Agreement-to-Expand-Global-Immunoassay-Portfolio/default.aspx

1 · Reply

Staska Feb. 17 at 12:17 PM

$QDEL CEO Brian Blaser acquired 10,540 shares at an average price of $23.59 (a $248,639 purchase), boosting his stake 35.69% to 40,073 shares (~$945K); the CFO also bought 3,370 shares, signaling insider confidence. https://www.marketbeat.com/instant-alerts/quidelortho-nasdaqqdel-ceo-brian-blaser-acquires-10540-shares-2026-02-13/

0 · Reply

TheTradeXchange Feb. 13 at 5:45 PM

FORM 4P $QDEL - QuidelOrtho Corp OFFICER - Chief Financial Officer: Busky Joseph M. P | 3,370 | $23.662 | $79,742

0 · Reply

CEOBuysDisclosures Feb. 13 at 5:45 PM

$QDEL CEO purchased 10,540 shares at $23.59 for a total of $248,661. Blaser Brian J. now owns 65,215 shares. https://ceo-buys.com

0 · Reply

Faster Cardiac Answers with High‑Sensitivity Troponin

Feb 18, 2026, 4:05 PM EST - 18 hours ago

QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference

Feb 11, 2026, 10:04 PM EST - 7 days ago

QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 4:05 PM EST - 7 days ago

QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 3, 2026, 7:12 AM EST - 16 days ago

QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards

Jan 22, 2026, 7:12 AM EST - 4 weeks ago

Strengthening the blood supply: Awareness, challenges and donor impact

Jan 21, 2026, 7:00 AM EST - 4 weeks ago

QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results

Dec 18, 2025, 9:17 AM EST - 2 months ago

Innovating Diagnostics and What's Next

Dec 3, 2025, 3:43 PM EST - 2 months ago

QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 24, 2025, 7:00 AM EST - 3 months ago

QuidelOrtho To Participate In Upcoming Investor Conferences

Nov 20, 2025, 9:00 AM EST - 3 months ago

The Power of Prevention: Detecting Diabetes Before It Strikes

Nov 6, 2025, 5:46 AM EST - 3 months ago

QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 3 months ago

QuidelOrtho Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:00 AM EST - 3 months ago

QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay

Oct 23, 2025, 6:45 PM EDT - 4 months ago

Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics

Oct 22, 2025, 7:00 AM EDT - 4 months ago

QuidelOrtho to Report Third Quarter 2025 Financial Results

Oct 16, 2025, 8:30 PM EDT - 4 months ago

QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025

Sep 25, 2025, 9:00 AM EDT - 5 months ago

Through Shades of Illness: Science Bytes Podcast Discusses Why Testing Matters

Sep 22, 2025, 7:00 AM EDT - 5 months ago

QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use

Aug 28, 2025, 7:30 AM EDT - 6 months ago

QuidelOrtho to Participate in the Baird 2025 Global Healthcare Conference

Aug 21, 2025, 4:30 PM EDT - 6 months ago

QuidelOrtho Completes Debt Refinancing

Aug 21, 2025, 9:00 AM EDT - 6 months ago

Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities

Aug 19, 2025, 4:05 PM EDT - 6 months ago

QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

Aug 13, 2025, 3:00 PM EDT - 6 months ago

QuidelOrtho Launches Certified Analyzer Program

Aug 6, 2025, 1:07 AM EDT - 7 months ago

QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:10 PM EDT - 7 months ago

QuidelOrtho Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 5:00 PM EDT - 7 months ago

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™

Jul 24, 2025, 9:00 AM EDT - 7 months ago

Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast

Jul 22, 2025, 4:30 PM EDT - 7 months ago

QuidelOrtho to Report Second Quarter 2025 Financial Results

Jul 17, 2025, 7:00 AM EDT - 7 months ago

Real Labs, Actual Decisions With Actionable Six Sigma Metrics

Jul 14, 2025, 7:00 AM EDT - 7 months ago

QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)

Jul 7, 2025, 7:00 AM EDT - 8 months ago

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

Jun 3, 2025, 4:10 PM EDT - 9 months ago

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

May 22, 2025, 4:30 PM EDT - 9 months ago

QuidelOrtho to Participate in Upcoming Investor Conferences

May 12, 2025, 9:30 AM EDT - 10 months ago

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)

May 7, 2025, 7:56 PM EDT - 10 months ago

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 10 months ago

QuidelOrtho Reports First Quarter 2025 Financial Results

Apr 23, 2025, 4:30 PM EDT - 10 months ago

QuidelOrtho to Report First Quarter 2025 Financial Results

Mar 10, 2025, 9:00 AM EDT - 1 year ago

QuidelOrtho® Introduces Results Manager™ System

Feb 24, 2025, 7:00 AM EST - 1 year ago

QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference

Feb 12, 2025, 7:50 PM EST - 1 year ago

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 4:05 PM EST - 1 year ago

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 13, 2025, 9:00 AM EST - 1 year ago

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

Jan 7, 2025, 12:48 AM EST - 1 year ago

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

Dec 31, 2024, 7:00 AM EST - 1 year ago

QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 7:00 AM EST - 1 year ago

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Nov 20, 2024, 3:08 PM EST - 1 year ago

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

Nov 20, 2024, 8:06 AM EST - 1 year ago

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

TGT POWL

Nov 19, 2024, 9:05 PM EST - 1 year ago

QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

VolatilityControl Feb. 18 at 4:40 PM

$QDEL QuidelOrtho operates diagnostics platforms with cyclical testing demand. Margin recovery depends on cost control. Base business remains stable.

0 · Reply

Staska Feb. 18 at 4:30 PM

0 · Reply

Staska Feb. 18 at 4:28 PM

1 · Reply

BillionerOfKing Feb. 18 at 2:05 PM

0 · Reply

ZacksResearch Feb. 17 at 5:05 PM

0 · Reply

ZacksResearch Feb. 17 at 4:05 PM

0 · Reply

Staska Feb. 17 at 12:23 PM

1 · Reply

Staska Feb. 17 at 12:17 PM

0 · Reply

TheTradeXchange Feb. 13 at 5:45 PM

FORM 4P $QDEL - QuidelOrtho Corp OFFICER - Chief Financial Officer: Busky Joseph M. P | 3,370 | $23.662 | $79,742

0 · Reply

CEOBuysDisclosures Feb. 13 at 5:45 PM

$QDEL CEO purchased 10,540 shares at $23.59 for a total of $248,661. Blaser Brian J. now owns 65,215 shares. https://ceo-buys.com

0 · Reply

BullYa Feb. 12 at 7:29 PM

$QDEL now it’s garbage 🗑️📉

0 · Reply

StocktwitsNews Feb. 12 at 6:13 PM

QDEL Stock Slumps On Mixed Wall Street Price Target Revisions After Q4 Report $QDEL $IJR $VTI https://stocktwits.com/news/equity/markets/qdel-stock-slumps-on-mixed-wall-street-price-target-revisions/cZRTtBrR4rs

0 · Reply

Chickenstick1 Feb. 12 at 2:43 PM

$QDEL 2.5x adjusted EBITDA.

0 · Reply

ZacksResearch Feb. 12 at 2:37 PM

$QDEL beats Q4… but it’s not all bullish ⚠️ Labs and global growth lifted sales past estimates, yet shrinking margins and weakness in respiratory dragged on profits — a classic top-line win, bottom-line pressure setup. Is this a temporary margin squeeze or a deeper issue? Get the full bull/bear breakdown 👉 https://www.zacks.com/stock/news/2861973/quidelortho-q4-earnings-and-revenues-beat-estimates-margins-down?cid=sm-stocktwits-2-2861973-teaser-33238&ADID=SYND_STOCKTWITS_TWEET_2_2861973_TEASER_33238

0 · Reply

gabescorner1995 Feb. 12 at 2:35 PM

$QDEL Completely gambled from news and won although the bears head and shoulders pattern was still there 83% gain

0 · Reply

ZacksResearch Feb. 12 at 1:37 PM

$QDEL beats EPS expectations but faces margin pressure 📉 QDEL delivered Q4 EPS of 46 cents, surpassing the Zacks Consensus Estimate by 6.9%. However, adjusted gross and operating margins contracted, with respiratory revenues down 13.9% on a reported basis. See the full breakdown here 👉 https://www.zacks.com/stock/news/2861973/quidelortho-q4-earnings-and-revenues-beat-estimates-margins-down?cid=sm-stocktwits-2-2861973-body-33233&ADID=SYND_STOCKTWITS_TWEET_2_2861973_BODY_33233

0 · Reply

Bazzzigar Feb. 11 at 9:59 PM

$QDEL JUNK

0 · Reply

StocktwitsEarnings Feb. 11 at 9:13 PM

$QDEL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$1.92 up 27.55% YoY • Reported revenue of $723.6M up 2.23% YoY • QuidelOrtho expects fiscal year 2026 total revenues between $2.7B, adjusted EBITDA of $630M, and free cash flow of $120M.

0 · Reply

StockBraker Feb. 11 at 9:06 PM

$QDEL

1 · Reply

AppUsageAlpha Feb. 4 at 1:34 PM

$QDEL is a diagnostics company with a focus on rapid point-of-care tests; its non-COVID business is growing, but the decline of pandemic-related revenue creates tough year-over-year comparisons.

0 · Reply

BullYa Jan. 27 at 12:23 PM

$QDEL ✅ heading $31 again then 💨🛫

0 · Reply

BullYa Jan. 26 at 5:32 PM

$QDEL should be 32~35 at normal range. Loading it up, long term is looking good. 52-week high at $45’s.

0 · Reply

Market Cap	1.57B
Revenue (ttm)	2.73B
Net Income (ttm)	-1.13B
EPS (ttm)	N/A
PE Ratio	11.12
Forward PE	10.12
Profit Margin	-41.45%
Debt to Equity Ratio	1.38

Volume	1,080,500
Avg Vol	1,057,096
Day's Range	N/A - N/A
Shares Out	67.93M
Stochastic %K	28%
Beta	0.68
Analysts	Sell
Price Target	$38.33